title: ÐÐ¸Ð³Ð°Ð½Ð´Ñ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ° ÑÐ¿Ð¸Ð´ÐµÑÐ¼Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ ÑÐ°ÐºÑÐ¾ÑÐ° ÑÐ¾ÑÑÐ° Ð² Ð¼ÐµÐ·ÐµÐ½Ñ Ð¸Ð¼Ð½ÑÑ ÑÑÑÐ¾Ð¼Ð°Ð»ÑÐ½ÑÑ ÐºÐ»ÐµÑÐºÐ°Ñ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Epidermal growth factor receptor ligands in mesenchymal stromal cells
Creators: name: ÐÑÑÐ¾Ð¼Ð¸Ð½Ð°, ÐÐ°ÑÐ¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2020
Subjects: ÑÐ½Ð´Ð¾Ð¼ÐµÑÑÐ¸Ð°Ð»ÑÐ½ÑÐµ Ð¼ÐµÐ·ÐµÐ½Ñ Ð¸Ð¼Ð½ÑÐµ ÑÑÑÐ¾Ð¼Ð°Ð»ÑÐ½ÑÐµ ÐºÐ»ÐµÑÐºÐ¸ (ÑÐÐ¡Ð)
ÑÐ¿Ð¸Ð´ÐµÑÐ¼Ð°Ð»ÑÐ½ÑÐ¹ ÑÐ°ÐºÑÐ¾Ñ ÑÐ¾ÑÑÐ° (Ð­Ð¤Ð )
ÑÐµÑÐµÐ¿ÑÐ¾Ñ ÑÐ¿Ð¸Ð´ÐµÑÐ¼Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ ÑÐ°ÐºÑÐ¾ÑÐ° ÑÐ¾ÑÑÐ° (ÑÐ­Ð¤Ð )
Ð°Ð¼ÑÐ¸ÑÐµÐ³ÑÐ»Ð¸Ð½ (AREG)
ÑÑÐ°Ð½ÑÑÐ¾ÑÐ¼Ð¸ÑÑÑÑÐ¸Ð¹ ÑÐ°ÐºÑÐ¾Ñ ÑÐ¾ÑÑÐ° - Î± (TGF-Î±)
ÑÐ¸Ð³Ð½Ð°Ð»Ð¸Ð½Ð³
endometrial mesenchymal stromal cells (eMSC)
epidermal growth factor (EGF)
epidermal growth factor receptor (EGFR)
amphyregulin (AREG)
transforming growth factor - Î± (TGF-Î±)
signaling

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð»Ð¸Ð³Ð°Ð½Ð´Ð¾Ð² ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ° Ð­Ð¤Ð  (Ð­Ð¤Ð , AREG Ð¸ TGF-Î±) Ð½Ð° ÑÐÐ¡Ð ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð»Ð¸Ð½Ð¸Ð¸ 2804. Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ ÑÐµÑÐ°Ð»Ð¸ÑÑ ÑÐ°ÐºÐ¸Ðµ Ð·Ð°Ð´Ð°ÑÐ¸, ÐºÐ°Ðº Ð¾ÑÐµÐ½ÐºÐ° ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð° ÑÐ­Ð¤Ð  Ð² ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð»Ð¸Ð½Ð¸ÑÑ ÐÐ¡Ð Ð¸ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¾Ð½Ð½ÑÑ Ð·Ð°Ð²Ð¸ÑÐ¸Ð¼Ð¾ÑÑÐµÐ¹ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð­Ð¤Ð , TGF-Î± Ð¸ AREG Ð½Ð° Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ñ ÑÐ­Ð¤Ð , Ð° ÑÐ°ÐºÐ¶Ðµ Erk1/2, Akt, Stat3 Ð² ÑÐÐ¡Ð ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, Ð²ÑÑÑÐ½ÐµÐ½Ð¸Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð»Ð¸Ð³Ð°Ð½Ð´Ð¾Ð² ÑÐ­Ð¤Ð  Ð½Ð° Ð¼Ð¸Ð³ÑÐ°ÑÐ¸Ñ ÑÐÐ¡Ð ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. ÐÑÐ»Ð¸ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ñ Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ¸ ÐºÑÐ»ÑÑÐ¸Ð²Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÐºÐ»ÐµÑÐ¾Ðº ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ ÑÐ»ÐµÐºÑÑÐ¾ÑÐ¾ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÐ°Ð·Ð´ÐµÐ»ÐµÐ½Ð¸Ñ Ð±ÐµÐ»ÐºÐ¾Ð² Ð¸ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð±Ð»Ð¾ÑÐ¸Ð½Ð³ ÐºÐ»ÐµÑÐ¾ÑÐ½Ð¾Ð³Ð¾ Ð»Ð¸Ð·Ð°ÑÐ°, Ð¼ÐµÑÐ¾Ð´ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½Ð¾Ð¹ ÑÐ°Ð½Ñ (scratch-assay). ÐÐ¾ Ð¸ÑÐ¾Ð³Ñ ÑÐ°Ð±Ð¾ÑÑ Ð¿Ð¾Ð»ÑÑÐµÐ½Ñ ÑÑÐ°Ð²Ð½Ð¸ÑÐµÐ»ÑÐ½Ð°Ñ Ð¾ÑÐµÐ½ÐºÐ° ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ñ ÑÐ­Ð¤Ð  Ð² ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð»Ð¸Ð½Ð¸ÑÑ ÐÐ¡Ð Ð¸ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¾Ð½Ð½ÑÐµ Ð·Ð°Ð²Ð¸ÑÐ¸Ð¼Ð¾ÑÑÐ¸ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ AREG, Ð­Ð¤Ð  Ð¸ TGF-Î± Ð½Ð° Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ñ ÑÐ­Ð¤Ð  Ð¸ ÑÐ¸Ð³Ð½Ð°Ð»ÑÐ½ÑÑ ÐºÐ¸Ð½Ð°Ð· (Erk1/2, Akt, Stat3), Ð²Ð¾Ð²Ð»ÐµÑÐµÐ½Ð½ÑÑ Ð² Ð¾ÑÐ½Ð¾Ð²Ð½ÑÐµ ÑÐ¸Ð³Ð½Ð°Ð»ÑÐ½ÑÐµ Ð¿ÑÑÐ¸ Ð¾Ñ ÑÐ­Ð¤Ð  Ð² ÑÐÐ¡Ð ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°, Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¾ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð»Ð¸Ð³Ð°Ð½Ð´Ð¾Ð² ÑÐ­Ð¤Ð  Ð½Ð° Ð¼Ð¸Ð³ÑÐ°ÑÐ¸Ñ ÑÐÐ¡Ð ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. ÐÑ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð»Ð¸, ÑÑÐ¾ ÑÐÐ¡Ð ÑÐºÑÐ¿ÑÐµÑÑÐ¸ÑÑÑÑ Ð´Ð¾Ð²Ð¾Ð»ÑÐ½Ð¾ Ð±Ð¾Ð»ÑÑÐ¾Ðµ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð¾ ÑÐ­Ð¤Ð . ÐÐ·Ð²ÐµÑÑÐ½Ð¾, ÑÑÐ¾ Ð­Ð¤Ð  Ð¸ Ð°Ð¼ÑÐ¸ÑÐµÐ³ÑÐ»Ð¸Ð½ ÑÑÐ°ÑÑÐ²ÑÑÑ Ð² ÑÑÑÑÐ¾Ð³ÐµÐ½-Ð·Ð°Ð²Ð¸ÑÐ¸Ð¼Ð¾Ð¹ ÑÐµÐ³ÑÐ»ÑÑÐ¸Ð¸ ÑÑÐ½ÐºÑÐ¸Ð¹ ÑÐ½Ð´Ð¾Ð¼ÐµÑÑÐ¸Ñ. Ð¢ÐµÐ¼ Ð½Ðµ Ð¼ÐµÐ½ÐµÐµ, Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð½Ð°ÑÐ¸Ð²Ð½ÑÑ Ð»Ð¸Ð³Ð°Ð½Ð´Ð¾Ð² ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ° Ð­Ð¤Ð  Ð½Ð° ÑÐÐ¡Ð, Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð½ÑÑ Ð¸Ð· Ð¼ÐµÐ½ÑÑÑÑÐ°Ð»ÑÐ½Ð¾Ð¹ ÐºÑÐ¾Ð²Ð¸, Ð¿ÑÐ°ÐºÑÐ¸ÑÐµÑÐºÐ¸ Ð½Ðµ Ð¸Ð·ÑÑÐµÐ½Ð¾, Ð² ÑÐ»ÐµÐ´ÑÑÐ²Ð¸Ðµ ÑÐµÐ³Ð¾ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð¾Ð±Ð»Ð°Ð´Ð°ÑÑ Ð²ÑÑÐ¾ÐºÐ¾Ð¹ ÑÑÐµÐ¿ÐµÐ½ÑÑ Ð½Ð¾Ð²Ð¸Ð·Ð½Ñ.
description: The given work is devoted to evaluation of the effect of EGFR ligands (EGF, AREG, and TGF-Î±) on human eMSC line 2804. In the course of this work, such tasks as estimation of the amount of EGFR in various lines of human MSC and tumor cells, investigation of concentration dependencies of the effect of EGF, TGF-Î± and AREG on activation of EGFR, as well as Erk1/2, Akt, Stat3 in human eMSC, clarification of the effect of EGFR ligands on migration of human eMSC were solved. Methods used in this work include cell culture, electrophoresis followed by immunoblotting of cell lysate, an experimental wound method (scratch-assay). As a result of this work, a comparative estimate of the content of EGFR in various lines of human MSC and tumor cells was obtained, concentration dependencies of the influence of AREG, EGF and TGF-Î± on activation of EGFR and signal kinases (Erk1/2, Akt, Stat3) involved in the main signal pathways from EGFR in human eMSC were studied, effect of EGFR ligands on human eMCS migration was investigated. We have showed that eMSC express quite a large amount of EGFR. EGF and amphiregulin are known to be involved in estrogen-dependent regulation of endometrial functions. However, effects of native EGFR ligands on eMCS isolated from menstrual blood havn't been studied, resulting in a high degree of novelty of this work.